NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Announces Update on Experimental Lingual Spray Drug Will
Be Presented at Anesthesia Meeting 


FLEMINGTON, N.J., April 14  /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. 
(BULLETIN BOARD: NVDL)  said an update on a lingual spray formulation of
propofol, the world's leading intravenous general anesthetic, will be presented
by its licensee and development partner, Manhattan Pharmaceuticals, Inc. 
(BULLETIN BOARD: MHTT) , at the 19th Annual Meeting of the Society for
Ambulatory Anesthesia, Seattle, April 29-May 2.

Manhattan scientists will describe recent progress in developing the
proprietary sedative in a presentation titled, "Propofol Lingual Spray:
Formulation Optimization and Stability".

In June 2003, Manhattan and NovaDel announced a joint program to develop a
safe, convenient, noninvasive lingual spray version of the widely used
sedative. The two companies believe the delivery of propofol via lingual spray
may provide many advantages over currently formulated sedatives.

The product would be indicated for patients undergoing in office or out patient
diagnostic or therapeutic procedures for which clinicians seek to tightly
control the onset, duration, and depth of sedation, with a level of reliability
and accuracy presently unachievable with existing sedatives.  The intended
benefits are expected to be better procedural outcomes and higher degrees of
patient comfort and satisfaction.

Manhattan owns the worldwide, exclusive rights to use NovaDel's proprietary
lingual spray technology to deliver propofol for preprocedural sedation.

About NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and
over-the-counter drugs.  The Company's proprietary lingual spray technology
delivery system offers the patient (i) fast onset of action; (ii) improved drug
safety by reducing the required drug dosage and reducing side effects; (iii)
improved patient convenience and compliance; and (iv) enhanced dosage
reliability.  The Company plans to develop such products independently and
through collaborative arrangements with major pharmaceutical and biotech
companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration
Statements, filed with the Securities and Exchange Commission.  In assessing
forward-looking statements contained herein, if any, the reader is urged to
carefully read all cautionary statements contained in such filings.

   Contact:
   Barry C. Cohen
   VP Business & New Product Development
   908 782-3431 x 2160
   NovaDel Pharma Inc.

   Thomas Redington
   203 222-7399
   212 926-1733
   

DATASOURCE: NovaDel Pharma, Inc.



CONTACT:  Barry C. Cohen, VP Business & New Product Development of

NovaDel Pharma Inc., [phone], ext. 2160; or Thomas Redington,

[phone], [phone], , for NovaDel

Pharma Inc.

Copyright